Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

NIH initiates interstitial cystitis trial

Aug. 16, 1999

Phase II testing of Alexion's C5 complement inhibitor also begins in renal diseases

Aug. 12, 1999

FDA puts hold on clinical study of Vasomax

Aug. 12, 1999

BioSpecifics Technologies announces positive preliminary results in Peyronie's disease therapy

Aug. 11, 1999

Mochida presents potent and selective heterocyclic cGMP-PDE inhibitors

July 30, 1999

NS-49: preclinical pharmacokinetics of potential new agent for stress incontinence

July 28, 1999

Rochester Medical's female incontinence device receives CE mark

July 28, 1999

Nitrosylated alpha-adrenoceptor antagonists as potential agents for impotence

July 27, 1999

Alza expands promotion of Ditropan XL for overactive bladder

July 27, 1999

Z-350, a novel treatment for BPH with a dual mechanism of action

July 21, 1999

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...